Dirk Reyn is a Pharmacist and MBA'er with International Marketing, Global Sales Management, Product Development, Crisis Management, Business Development and General Management/biotech CEO skills acquired in the international pharmaceutical industry over a period of more than 38 years in both big and small companies and in different continents.  He was a key player in at least 6 major pharma licensing and M&A deals in his capacity as head of BD for Europe while working for JNJ. After his tenure in big pharma (Lilly and JNJ), he was start-up CEO and founder of different companies including Movetis (2006), a public (Euronext) biopharmaceutical spin-off company from Janssen Pharmaceutica that was acquired by Shire, Progress Pharma (2012) that worked on a GI asset (Lipid, Heidelberg) before it was acquired by Nestle, eTheRNA (2015), a mRNA technology spin-off from the Free University of Brussels, and Spectricity (2018), an Imec spin-off with the smallest spectrometer on the planet.  He currently is one of the three Managing Partners of the Bioqube Factory Fund (2020), a specialized biotech investment Fund with 110 million under management. He is also President of Flanders.bio the organization of biotech companies in Flanders.